Objective : The present study is aimed to evaluate the effectiveness of short wave diathermy and
ultrasound therapy for the management of patients with knee osteoarthritis
Methodology : all patients who referred to the Medical Rehabilitation Unit in Baghdad Teaching
Hospital and Sadr A!-Qanat Center. The period of the study was from October 2004 to April 2005, total
number of patients was 24 (9 male and 15 female). Age range of patients was 42-70 years. Complete
clinical and radiological examinations were achieved on all patients and referred to the Medical
Rehabilitation Unit for physiotherapy. Short wave diathermy and ultrasound therapy were applied on
all patients.
Results : Demographic distribution revealed that female gender, the ages more than 50 year, the weight
with grade II obesity were the most affected. Clinical observations indicated that chronic and severe
cases were the most obvious. The study revealed that deformity, muscle wasting, local inflammation,
and effusion were recorded in most patients. Outcomes of treatment with short wave and ultrasound
therapies were nearly equally regarding their well-effectiveness, patient's acceptance, and patient's
improvement. It was concluded that the ultrasound therapy is more preferable than short wave
diathermy in the management of oedema accompanying chronic knee osteoarthritis. Recommendation :
Further cohort studies are required to evaluate the effects of these procedures on a large sample of
patients
Back ground: Fibromyalgia syndrome (FMS) is a common chronic musculo-skeletal disorder resulting in chronic widespread pain impacting on quality life.
Objectives: To assess the relationship between FMS and knee osteoarthritis (KOA) and to evaluate the predictors of this relationship if present.
Patients and Methods: One hundred Iraqi KOA patients and 100 healthy controls were included in this cross-sectional study. Full history was taken and complete clinical examination was done for all patients. Baseline characteristics [age, sex, duration, body mass index (BMI), waist circumference, family history (Hx) of KOA, smoking history, and drug history.] were also documented. Laboratory analysis included complete blood count, erythrocyte
Background: Osteoarthritis (OA) is disorder of diarthrodial joints characterized clinically by pain and functional limitation. Rheumatoid factor (RF) represents one of routine laboratory tests that done for all patients have joint complaints. Chloroquine phosphate (CQP) is a disease modifying antirheumatic drug (DMARD) used for patients suffer from knee osteoarthritis (KOA) in order to reduce their RF value and improves the disease status.
Objective: To evaluate the effect of chloroquine phosphate on rheumatoid factor (RF) level in serum of patients with knee osteoarthritis KOA) Design: case report.
Subjects and methods: RF value were assessed quantitatively by ELISA technique before and after tre
Background: The acute phase response is a major pathophysiologic phenomena that accompanies inflammation whether acute or chronic. The complements 3 (C3), complement4
(C4) and C-reactive protein (CRP) are positive acute phase proteins (+ve APPs) their production is increased by hepatocyte in osteoarthritis (OA). Chloroquine (CQ) which is a diprotic weak base traditionally used to treat malaria.Todate, the phosphate salt of CQ is used to decrease +ve APPs.
Objective: To evaluate the role of chloroquine phosphate on acute phase proteins C3, C4 and Creactive protein in patients with knee OA.
Subjects and methods :A total of seventy four patients (45 female and 29male) were selected randomly from the outpati
Objective: Knee osteoarthritis is a common disabling chronic disease globally. Many pharmacological agents have been used efficiently in treatment of knee osteoarthritis. This study aims to evaluate metformin and serratiopeptidase together in treatment and stop of osteoarthritis progression by different mechanisms. Methods: Present study was a randomized clinical trial study conducted in Al-Kindi teaching hospital through the period from 1st January to 30th of May, 2017 on two groups of 80 osteoarthritis patients (group I; treated with metformin 850 mg oral tablets) and (group II; treated with metformin 850 mg oral tablets and serratiopeptidase 20 mg oral tablets). Parameters of two groups were compared with those of 40 normal healt
... Show More
(4)
Osteoarthritis (OA) is recognized as a main public health difficult. It is one of the major reasons of reduced function that diminishes quality of life worldwide. Osteoarthritis is a very common disorder affecting the joint cartilage. As there is no cure for osteoarthritis, treatments currently focus on management of symptoms. Pain relief, improved joint function, and joint stability are the main goals of therapy. The muscle weakness and muscle atrophy contribute to the disease process. So, rehabilitation and physiotherapy were often prescribed with the intention to alleviate pain and increase mobility. Medical therapy provides modest benefits in pain reduction and functional improvement; however, non-steroidal anti-inflammatory dru
... Show More
Osteoarthritis is the most prevalent arthritic disease and a leading cause of disability. The pathogenesis of osteoarthritis involves multiple etiologies, including variable degree of synovial inflammation. Metformin and pioglitazone could potentially reduce the levels and activity of inflammatory mediators. This may consider as a new therapeutic approach added to the current used drugs in an attempt to decrease the pain, inflammation, and improve daily activity and quality of life in patients with knee osteoarthritis.
This study designed to evaluate the clinical utility of using metformin or pioglitazone as anti-inflammatory agents in combination with non-steroidal anti-inflammatory drugs (NSAID) of selective type of cyclooxygen
... Show More
(4)
Background: Osteoarthritis is the most common joint disorder. Treatment is usually limited to short term symptom relived and is by no means satisfactory.
The acute phase response is a major pathophysiologic phenomenon that accompanies inflammation whether acute or chronic. Complement (C3 and C4) and C - reactive protein (CRP) are positive acute phase proteins (+ ve APPs ). Their production takes place in hepatocyte and the blood concentration of these parameters are increased in osteoarthritis (OA). Chloroquine (CQ) is a diprotic weak base traditionally used to treat malaria. Recently the phosphate salt of CQ is used to decrease this type of (+ve APPs) . In this study, patients who suffered from knee osteoarthritis (KOA) are treated with oral dosage form of chloroquine phosphate (CQP) for one month, twice daily. Our results demonstrate that CQP improves the patient status by decreas
... Show More
Background: New data suggests that joint damage in Knee Osteoarthritis (KOA) may be caused by systemic factors like adipose tissue products; Adipokines, which may provide a
metabolic link between obesity & KOA. Recently, one of the known adipokines named LEPTIN has been linked to KOA because it can be detected in serum & synovial fluid of
patients with KOA.
Objective: To evaluate the contribution of Leptin & serum lipids to the pathophysiology of Osteoarthritis in Iraqi patients with Knee OA.
Subjects& Methods: The study was carried on 90 subjects divided into four groups: Knee Osteoarthritis cases group (n=60). Control group (n=30). Obese subjects group (n=60).
Non-obese subje
Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) mostly associated with renal and hepatic adverse effects, and the adjunct use of compounds with potent protective effects, like silymarin, may be one of the choices to avoid these effects. This project was designed to evaluate the protective effect of silymarin against the suspected renal and hepatic injury induced with long term use of NSAIDs; 220 patients with osteoarthritis were randomized into 5 groups and treated with either silymarin 300mg/day alone, piroxicam 20mg/day alone, meloxicam 15mg/day alone or the combination of each of them with silymarin for 8 weeks. The renal and hepatic functions were evaluated before starting treatment and after 8 weeks including assessm
... Show More